Terminated PHASE3 INTERVENTIONAL 2-arm NCT04857840

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) (REFRESH)

A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients With Difficult-to-treat/Resistant Hypertension.

Sponsor: PRA Health Sciences

Conditions Hypertension (HTN)

Interventions Firibastat (QGC001) Period 1

Updated 5 times since 2021 Last updated: Jan 13, 2023 Started: Aug 5, 2021 Primary completion: Jan 9, 2023 Completion: Jan 9, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No Efficacy demonstrated inn the QGC001-3QG1 study

Other terminated trials from PRA Health Sciences

See all terminations from PRA Health Sciences

This PHASE3 trial investigates Hypertension (HTN) and is currently terminated or withdrawn. PRA Health Sciences leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Feb 2023 — Jul 2024 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated
Oct 2021 — Feb 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PRA Health Sciences
Quantum Genomics SA

Data source: Quantum Genomics SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manassas, United States
• Toronto, Canada